NCT07363642

Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

TAPER: A Prospective, Interventional, Multicentre, Single-Arm, Phase 3b Study to Evaluate the Step-Down of Maintenance Therapy in Patients With Severe Asthma Treated With Tezepelumab

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 12 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.

Detailed description

This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential and safety of stepping down background maintenance therapy following the initiation of Tezepelumab treatment in Chinese patients with maintenance of asthma control. This study will be conducted at approximately 70 study sites in China. The study duration for each patient will be up to 52 weeks. Approximately 400 patients with severe asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs or theophylline will be enrolled into this single arm study.

Conditions

• Severe Asthma

Interventions

Type	Name	Description
DRUG	Tezepelumab	Severe asthma taking medium-high dose ICS/LABA with up to one additional controller will be enrolled into this single arm treatment

Timeline

• Start date: 2026-01-28
• Primary completion: 2027-08-07
• Completion: 2029-03-31
• First posted: 2026-01-23
• Last updated: 2026-03-18

Locations

75 sites across 1 country: China